humax-il8

mAbexperimental

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • humax-il8
  • humax-il8

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05148234Phase 1/Phase 2 (Phase 2)Dec 24, 2021National Cancer Institute (NCI)
NCT04848116Phase 2Apr 24, 2021Bristol-Myers Squibb, Johns Hopkins University
NCT04572451Phase 1Jan 31, 2021Bristol-Myers Squibb, University of Pittsburgh
NCT04347226Phase 2Apr 16, 2020Bristol-Myers Squibb, Columbia University
NCT04123379Phase 2Nov 30, 2019Bristol-Myers Squibb, Icahn School of Medicine at Mount Sinai
NCT03689699Phase 1/Phase 2 (Phase 2)Oct 31, 2018Bristol-Myers Squibb, Columbia University
NCT03400332Phase 1/Phase 2 (Phase 2)Jan 31, 2018Bristol-Myers Squibb
NCT02536469Phase 1Aug 1, 2015Bristol-Myers Squibb
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit7222015
Columbia UniversityAcademic/Hospital2212018
Icahn School of Medicine at Mount SinaiAcademic/Hospital1112019
Johns Hopkins UniversityAcademic/Hospital1112021
National Cancer Institute (NCI)Government1112021
University of PittsburghAcademic/Hospital1112021
6 organizations
Page 1 / 1